Author's response to reviews

Title: Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial.

Authors:

Fabrizio Mecenate (famecenate@yahoo.it)
Adriano M Pellicelli (adriano.pellicelli@tiscal.it)
Mario Romano (mario.romano@aslromab.it)
Giuseppe Barbaro (g.barbaro@tin.it)
Angelo Barlattani (angelo@barlattani.it)
Ettore Mazzoni (ettor.mazzoni@tiscali.it)
Maria Elena Bonaventura (mebonaventura@alice.it)
Lorenzo Nosotti (l.nosotti@virgilio.it)
Pasquale Arcuri (p.arcuri@katamail.com)
Giorgio Barbarini (g.barbarini@libero.it)
Amerigo Paffetti (amerigo.paffetti@uniroma1.it)
Antonio Picardi (adriano.pellicelli@tiscali.it)
Arnaldo Andreoli (aandreoli@scamilloforlanini.rm.it)
Fabrizio Soccorsi (fsoccor@tin.it)
Cecilia D'Ambrosio (cdambrosio@scamilloforlanini.rm.it)

Version: 3 Date: 26 December 2009

Author's response to reviews: see over
Replay to the Referee Prof  P. Almasio

Point 1. In the method section we have replaced “1000-1200 mg/day” with “800-1200 mg/day” as reported in the abstract. Furthermore in subsection study design we have specified the dosage of ribavirin according to patient weight “at a dosage of 800 mg/day (for those with a weight of < 65 kg), 1000 mg/day (for those with a weight between 65 and 85 kg) or 1200mg/day (for those with a weight > 85 Kg)”

Point 2. The title of the legend table 2 was replaced with the following title as suggested by the referre “Patients characteristics according to achievement of rapid virological response”

Point 3. We have made any required changes to the format of our paper

Sincerely Yours

Adriano M Pellicelli MD